$Refractory hemophagocytic lymphohistiocytosis secondary to polatuzumab vedotin plus rituximab and bendamustine$

Refractory hemophagocytic lymphohistiocytosis secondary to polatuzumab vedotin plus rituximab and bendamustine

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of hematology 2024-03, Vol.103 (3), p.1017-1019
Hauptverfasser:	Lv, Kebing, Kong, Fancong, Yu, Min, Zhou, Yulan, Li, Fei
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Bendamustine Hydrochloride - adverse effects Hematology Humans Immunoconjugates - therapeutic use Letter to the Editor Lymphohistiocytosis, Hemophagocytic - chemically induced Lymphohistiocytosis, Hemophagocytic - complications Lymphohistiocytosis, Hemophagocytic - drug therapy Lymphoma, Large B-Cell, Diffuse - drug therapy Medicine Medicine & Public Health Oncology Rituximab - adverse effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!